Omnipod® 5 with FreeStyle Libre 3 Plus sensor integration

Omnipod 5 Automated Insulin Delivery System and FreeStyle Libre 3 Plus sensor: A simpler, smarter way to manage your diabetes

Experience the convenience of the only tubeless automated insulin delivery system integrated with the FreeStyle Libre 3 Plus sensor. With up to 15 days of continuous sensor wear, you can monitor your glucose levels and manage your Pod all from one place, your dedicated Omnipod 5 Controller. This seamless integration is designed to offer another choice to manage diabetes your way.

Omnipod 5 controller, pod and FSL3 sensor without adhesive Omnipod 5 controller, pod and FSL3 sensor without adhesive
Pod and sensor shown without the necessary adhesive.

How the Omnipod 5 System works

When paired with a compatible sensor like the FreeStyle Libre 3 Plus sensor, Omnipod 5 automatically delivers insulin for up to three days (72 hours), adjusting insulin levels every five minutes to help protect against highs and lows1,2 — day and night, even while you sleep.

Clinical and real world evidence shows Omnipod® 5 can support more than 80% time in range with optimized settings*.

Explore Omnipod®
*Retrospective RWE data on file. 2025. Results shown for users with optimized settings including sufficient CGM data (≥75% of days with ≥220 readings), ≥90% time in Automated Mode, ≥5 bolus/day and an average Target Glucose of 110-115 mg/dL (6.1-6.4 mmol/L). Optimized settings: ISF x TDI ≤1500, I:C Ratio x TDI ≤350. RF-062025-00014.

Key features - Omnipod 5 with FreeStyle Libre 3 Plus sensor integration

Check glucose and manage insulin delivery directly from the dedicated Omnipod 5 Controller

Families with children living with diabetes and other caregivers can use the compatible  LibreLinkUp app. to easily monitor glucose at anytime.

Works with Omnipod 5 Pods compatible with FreeStyle Libre 3 Plus sensor

Convenient 15-day sensor wear

FreeStyle Libre logo FreeStyle Libre logo
Omnipod with Freestyle Libre 3 plus sensor Omnipod with Freestyle Libre 3 plus sensor
Pod and sensor shown without necessary adhesive.
Podder wearing an Omnipod, lounging on the sofa Podder wearing an Omnipod, lounging on the sofa

Start your journey with tubeless, automated insulin delivery

Explore Omnipod 5 your way: try it, see it in action, or speak with someone to learn more.

Check Your Coverage

Register for a Pod 101 Webinar session

Order a Free Pod Experience Kit

Learn More About Omnipod 5

Video Tutorials

Child sleeping while wearing Omnipod 5 pod and FSL3 sensor Child sleeping while wearing Omnipod 5 pod and FSL3 sensor

Have questions about Omnipod 5 and FreeStyle Libre 3 Plus integration?

Check out our complete list of FAQs to learn more about Omnipod 5 with FreeStyle Libre 3 Plus integration and get answers to common questions: Omnipod® 5 with FreeStyle Libre FAQs

1. Brown S. et al. Diabetes Care. 2021;44:1630-1640. Prospective pivotal trial in 240 participants with T1D aged 6 - 70 yrs. Study included a 14-day standard therapy (ST) phase followed by a 3-month Omnipod 5 hybrid closed-loop (HCL) phase. Mean time in range (3.9-10.0 mmol/L or 70- 180mg/dL) in adults/adolescents as measured by CGM: ST = 64.7%, 3-mo Omnipod 5 = 73.9%, P<0.0001. Mean time in range (3.9-10.0 mmol/L or 70-180mg/dL) in children as measured by CGM: ST = 52.5%, 3-mo Omnipod 5 = 68.0%, P<0.0001. Mean time in hyperglycaemic range (>10.0 mmol/L or >180mg/dL) as measured by CGM in adults/adolescents and children ST vs. 3-mo Omnipod 5: 28.9% vs. 22.8%; 44.8% vs 29.7%, P<0.0001, respectively. Mean time in hypoglycaemic range in adults/adolescents (<3.9 mmol/L or <70mg/dL as measured by CGM) as measured by CGM: ST = 1.89%, 3- mo Omnipod 5 = 1.32%, P<0.0001. Mean time in hypoglycaemic range in children (<3.9 mmol/L or <70mg/dL as measured by CGM): ST = 2.21%, 3-mo Omnipod 5 = 1.78%, P<0.0456.

2. Sherr J. et al. Diabetes Care. 2022; 45:1907-1910. Single-arm multicenter clinical trial in 80 pre-school children (aged 2-5.9 yrs) with T1D. Study included a 14-daystandard therapy (ST) phase followed by a 3- month AID phase with Omnipod 5 system. Mean time in range (3.9-10.0 mmol/L or 70- 180mg/dL) as measured by CGM in children ST vs. 3-mo Omnipod 5: 57.2% vs 68.1%, P<0.0001. Mean time in hyperglycaemic range (>10.0 mmol/L or >180mg/dL) as measured by CGM in children ST vs. 3-mo Omnipod 5: 39.4% vs. 29.5%, P<0.0001, respectively. Mean time in hypoglycaemic range (<3.9mmol/L or <70mg/dL as measured by CGM) ST = 3.43% vs Omnipod 5: 2.46%, P<0.0001.